Quarterly report [Sections 13 or 15(d)]

Business Combination - Intangible Assets Acquired (Details)

v3.26.1
Business Combination - Intangible Assets Acquired (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended 15 Months Ended
Jun. 30, 2026
Jun. 30, 2026
Dec. 31, 2025
Dec. 31, 2025
Indefinite-Lived Intangible Assets [Roll Forward]        
Impairment $ 9,190,897 $ 9,190,897 $ 0  
Goodwill        
Combination Date Fair Value   12,401,118    
Impairment   0    
Carrying Value 11,961,275 11,961,275 12,401,118 $ 12,401,118
Pharmagesic        
Indefinite-Lived Intangible Assets [Roll Forward]        
Combination Date Fair Value   68,985,026   69,500,000
Impairment   (9,190,897)    
Translation Adj   (2,446,760)   (514,974)
Carrying Value 57,347,369 57,347,369 68,985,026 68,985,026
Goodwill        
Combination Date Fair Value   12,401,118   12,493,727
Translation Adj   (439,843)   (92,609)
Carrying Value 11,961,275 11,961,275 12,401,118 12,401,118
Pharmagesic | Halneuron for Cancer Related Pain        
Indefinite-Lived Intangible Assets [Roll Forward]        
Combination Date Fair Value   59,456,159   59,900,000
Translation Adj   (2,108,790)   (443,841)
Carrying Value $ 57,347,369 57,347,369 59,456,159 59,456,159
Pharmagesic | Halneuron for Chemotherapy Induced Neuropathic Pain        
Indefinite-Lived Intangible Assets [Roll Forward]        
Combination Date Fair Value   9,528,867   9,600,000
Impairment   (9,190,897)    
Translation Adj   $ (337,970)   (71,133)
Carrying Value     $ 9,528,867 $ 9,528,867